Novartis to build fourth US radioligand therapy facility in Florida
The facility forms a key component of the company’s $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments
Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered